SUMMARY
following MUS, and can be a most distressing and potentially irreversible complication to rectify (17, 18) .
MESH IN POP
Mesh use for abdominal sacrocolpopexy dates back to 1962 (19) and is well established through long-term data (20, 21) . On the other hand, transvaginal repairs with either self-fashioned prolene mesh or commercial mesh kits are very controversial. Mesh for anterior repair may improve anatomic outcomes but has not demonstrated a clear benefit regarding quality of life and patient satisfaction in a recent meta-analysis (21, 22) . Efficacy of mesh repairs for vault repair and posterior repair has not been demonstrated, with low level evidence and short term studies (21, 22) . Most frequently cited complications are vaginal extrusion and exposure ranging from 5.8 to 20% (22, 23) De novo dyspareunia and pelvic pain is also a significant concern reported in 1 to 69% (24) . Pain seems to be related to the amount of implanted mesh and likely partially attributable to mesh contraction (23) . Fistulae may involve the urinary tract and/ or colo-rectal tract requiring aggressive intervention. (See Figure1.) Recurrent prolapse, infection, neuromuscular impairment, vaginal shrinkage, psychological problems and death have been reported complications associated with mesh for transvaginal POP repair (21) .
FDA NOTIFICATIONS
The FDA released a Public Health Notification in October 2008 in response to complications associated with urogynecologic use of surgical mesh (25) . The FDA conducted a search of the adverse events in Manufacturer's and User Device Experience (MAUDE) database, revealing 3,979 cases from January 2005 to December 2010 with a 5 fold increase in reports of adverse events in POP repairs from January 2008 to December 2010 (21) . An "Update on the Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse" was issued by the FDA in July 2011. Unlike the 2008 notification, the 2011 FDA Safety Communication stated that complications "are NOT rare" and that "transvaginally placed mesh in POP repairs does NOT conclusively improve clinical outcomes over traditional non-mesh repairs" (21) . The Safety Communication aimed to educate the public and health care providers with adverse events relating to these devices and provided recommendations for informed decision-making regarding transvaginal mesh (21) . In September 2011, an advisory panel of experts assembled for an open public hearing and presentations by both industry and the FDA to address questions regarding mesh safety for urogynecological applications for POP and SUI (21) . Regarding transvaginal placement of mesh, the advisory panel reached a number of consensus including the following: (i) The safety, efficacy and benefit ratio is not well established in transvaginal mesh.
(ii) Improved premarket studies comparing mesh to non-mesh options need at least 1 year follow-up. Although it is recommended that mesh and device complications are reported to the FDA through its MedWatch, the FDA Safety Information and Adverse Event Reporting program or respective national equivalent, surgeons and clinicians underreport adverse events as the reporting process can be time consuming and is completely voluntary (21) . Many acknowledge the need for a comprehensive registry of mesh use and outcomes (27) (28) (29) . Until such a national registry exists, recognition of device-associated complications will be further delayed until reported in the literature, thus exposing even more patients to these risks (28) . Fortunately, a national registry of outcomes of mesh in incontinence and prolapse is underway in both Australia and the United Kingdom, initiated by their national urogynecological societies (30) . The Urogynaecological Society of Australia (UGSA) database encourages its members to report their outcomes by offering the database at a low annual cost, giving CME credits for participating and arguing for the greater good since accurate surgical data will better support clinical and regulatory decisions (30) . Companies marketing mesh products should be encouraged to employ code numbers and tracking systems to make identification and follow-up of mesh easier.
CLASSIFICATION OF MESH COMPLICATIONS
A classification system of complications related directly to the insertion of prosthesis in female pelvic floor surgery has been instituted by both the International Urogynecological Association (IUGA) and International Continence Society (ICS) in efforts to standardize terminology for more precise reporting of complications which should help facilitate the implementation of a reliable registry (28, 31) . (See Table 2 .1 for a list of the terminology.) The classification system coding is based on category of complication, time of clinical diagnosis and site of complication (31) . Pain is subclassified into 5 grades ranging from a (asymptomatic/ no pain) to e (spontaneous pain) (31) . Although a patient may suffer different complications at different times, all complications should be listed with the final category for a single complication reported at its maximal score (31) . (See 
INVESTIgATIONS
As the long-term consequences of mesh are still unknown, patients with mesh placed for SUI and POP should have long-term (>10 years) follow-up to monitor for complications or symptoms (32) (33) (34) .
Complications with mesh can occur several years later and the field is becoming increasingly litigious (34, 35) . Patients with mesh who do not have complications should not undergo mesh explantation (32) . A detailed history should screen for vaginal discharge, vaginal bleeding, pelvic or groin pain, dyspareunia, hispareunia, UTIs, urinary urgency, incomplete emptying, prolonged or slow urinary stream as well as bowel complaints. Onset of the symptoms, type of mesh used preferably based on an operative report, prior pelvic surgeries, investigations and treatments should be attained. A pelvic exam is necessary to assess for mesh exposure, prominence of scar tissue, recurrence of prolapse or SUI, and areas of tenderness or discomfort. In severe cases, patients unable to tolerate the exam may require an examination under anesthesia. Cystourethroscopy can be useful to identify mesh exposed in the lower urinary tract ( Figure 2 ) and distortion of the urethral lumen (Figure a) . For voiding complaints, urodynamic studies and voiding cystourethrogram (VCUG) have been useful. For bladder outlet obstruction following MUS placement, patients may demonstrate detrusor overactivity but more consistently will exhibit a prolonged or intermittent flow curve with an elevated detrusor pressure on urodynamic testing (Figure b) . Another finding of bladder obstruction secondary to MUS on VCUG is urethral narrowing and kinking at the level of the MUS with proximal urethral dilatation (Figure3c) (36) . Present imaging strategies with MRI and ultrasound are generally of limited use for pre-surgical planning, but sometimes identify the mesh.
Management Options:
Vaginal extrusions and exposure may be managed conservatively if exposure is < 1cm and not associated with any complicating factors (23, 37) . Local estrogen therapy is often employed but the literature reflects mixed results (23, 38) . If vaginal extrusion/exposure is larger or fails to heal satisfactorily with conservative measures, mesh excision should be considered (23, 29, 37, 38) . Often a limited excision of mesh is attempted under local anesthesia in cases of small persistent areas of vaginal mesh exposure (29, 38) . Management of mesh involving the urinary tract has been reported with excision via either the vaginal or abdominal approaches, endoscopically with ablation with holmium laser or transurethral resection with electrocautery (39, 40) . Combined laparoscopic and endoscopic procedures have also been described (41).
For urinary retention following placement of a suburethral tape that persists for > 1 week, loosening the sling or sling incision is recommended. Despite a prior sling incision at another institution, we caution the reader about some patients who continue to have obstructive symptoms and clinical evidence of obstruction on urodynamics and VCUG, and may ultimately require excision of the tape and/or urethrolysis. It is likely that the longer the obstruction goes untreated, prolonged compression and ischemia of the midurethra can result in permanent scarring of the urethral lumen and consequential voiding dysfunction and bladder remodeling (42) . Behavioral therapy and anticholinergics have been reported for de novo detrusor overactivity following sling placement. Urgency symptoms frequently occur as a result of BOO; and thus BOO be excluded for any de novo symptoms after a sling procedure (43) (44) (45) . In this case, tape excision to relieve the obstruction would be necessary. Figure 3 . Persistent lower urinary tract symptoms (frequency, urgency and mixed urinary incontinence), recurrent UTIS and incomplete emptying in a 50 year old woman who underwent a "loosening of her tape" at 3 months post-op. Cystoscopy revealed no exposed tape to explain her UTIs, but a very narrow lumen with elevation and flattening of urethral floor depicted by the arrow in Figure 3a . Urodynamics (3b) and voiding cystogram confirmed obstruction and its site (arrow on 3c). Tape loosening or incision does not always release an obstruction completely and persistent symptomatology should raise the concern for residual obstruction. In some patients, either complete or partial removal of the mesh is the only effective treatment modality. Mesh removal can be performed transvaginally or in a combined abdominal-vaginal approach. Mesh removal is challenging as visualization is often limited and extent of tissue damage from the mesh is often unknown. Success of mesh removal often depends on surgical experience in dealing with these complications. As a result, many patients travel great distances to tertiary referral centers to deal with their mesh complication as a last resort (42) . Tape excision technique is depicted in Figure 4 (46). Specific complications following tape removal include recurrent incontinence, urethral stricture, persistent pain, bladder neck injury, vesicovaginal fistula and need for repeat surgery. Complications following removal of transvaginal mesh are related to the affected compartment. For apical and anterior meshes, bladder and ureteric a b c injury are of particular concern. Following mesh removal, we routine perform cystoscopy with indigo carmine to exclude ureteric injury. For mesh complications involving the posterior compartment, bowel injury and need for colostomy have been reported (23) . Other complications associated with mesh excision include large vaginal defects, possibly requiring skin grafting, residual pain which can be unremitting and life altering, and/or need for repeat surgery.
CONCLUSIONS
Management of mesh complications in POP and SUI is a rapidly growing field for surgeons, therapists and lawyers. These complications emphasize the need for more deliberate and careful consideration by both the patient and the surgeon prior to surgery. The literature reporting mesh complications is mostly retrospective. As surgeons, we are unable to predict who will suffer an adverse event. It is unclear whether the contributing factors of these devastating complications result from poor surgical technique, deficient training, infection, patient factors or an inherent defect of the synthetic material (27) . Marketing strategy rather than evidence-based data resulted in rapid adoption of mesh for POP (42, 47) . In retrospect, surgical expertise with specialized training in proper patient selection, mesh insertion and management of associated complications is now advocated (21, 28, 32) . Tightening FDA approval with more rigorous safety and efficacy testing for the licensing of new surgical devices will be necessary to improve patient safety and trust (21, 32, 38, 47) . There are still many unanswered questions in understanding vaginal tissue, its aging process and how exactly mesh placement affects the vaginal wall healing and inflammatory responses (42) . We also need to better understand mesh properties and biomechanics to ultimately create a more biologically compatible material to avoid potentially devastating and permanent complications (27) . With increased vigilance, understanding and expertise in the field, it will be possible to achieve the best outcomes for our patients.
